DK2004183T3 - Mazindol-kombination i behandlingen af opmærksomhedsunderskud/hyperaktivitet - Google Patents

Mazindol-kombination i behandlingen af opmærksomhedsunderskud/hyperaktivitet

Info

Publication number
DK2004183T3
DK2004183T3 DK07727980.0T DK07727980T DK2004183T3 DK 2004183 T3 DK2004183 T3 DK 2004183T3 DK 07727980 T DK07727980 T DK 07727980T DK 2004183 T3 DK2004183 T3 DK 2004183T3
Authority
DK
Denmark
Prior art keywords
mazindol
hyperactivity
treatment
combination
attention deficit
Prior art date
Application number
DK07727980.0T
Other languages
English (en)
Inventor
Eric Konofal
Original Assignee
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of DK2004183T3 publication Critical patent/DK2004183T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK07727980.0T 2006-04-11 2007-04-11 Mazindol-kombination i behandlingen af opmærksomhedsunderskud/hyperaktivitet DK2004183T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0603197A FR2899476B1 (fr) 2006-04-11 2006-04-11 Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
PCT/EP2007/053512 WO2007116076A1 (fr) 2006-04-11 2007-04-11 Association du mazindol dans le traitement du deficit de l'attention/hyperactivite

Publications (1)

Publication Number Publication Date
DK2004183T3 true DK2004183T3 (da) 2013-09-23

Family

ID=36791558

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07727980.0T DK2004183T3 (da) 2006-04-11 2007-04-11 Mazindol-kombination i behandlingen af opmærksomhedsunderskud/hyperaktivitet

Country Status (16)

Country Link
US (9) US8293779B2 (da)
EP (2) EP2004183B1 (da)
JP (2) JP2009533388A (da)
CN (2) CN101420953A (da)
AU (1) AU2007235860B2 (da)
CA (1) CA2648943C (da)
DK (1) DK2004183T3 (da)
ES (2) ES2427570T3 (da)
FR (1) FR2899476B1 (da)
IL (1) IL194623A (da)
MA (1) MA30330B1 (da)
NZ (1) NZ572002A (da)
PL (2) PL2004183T3 (da)
PT (1) PT2004183E (da)
TN (1) TNSN08397A1 (da)
WO (1) WO2007116076A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062577A2 (en) * 2003-01-03 2004-07-29 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
WO2011068977A1 (en) * 2009-12-02 2011-06-09 Supernus Pharmaceuticals, Inc. Method of treatment of cns disorders
MX344189B (es) * 2010-03-31 2016-12-08 Supernus Pharmaceuticals Inc Formulaciones de mazindol.
CN102671189B (zh) * 2012-05-10 2013-11-20 南京特丰药业股份有限公司 一种蛋白琥珀酸铁增溶方法及其口服溶液制剂
ITMI20131147A1 (it) 2013-07-09 2015-01-10 Biofer Spa Nuova via di somministrazione del ferro, e nuove formulazioni adatte a tale scopo.
MA55045A (fr) * 2016-03-09 2021-12-29 Nls Pharmaceutics Ag Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)
WO2017152974A1 (en) 2016-03-09 2017-09-14 Nls-1 Pharma Ag A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
EP3678661A1 (en) 2017-09-07 2020-07-15 NLS-1 Pharma AG Mazindol treatment for heroin dependence and substance use disorder
CN115607575A (zh) * 2022-09-19 2023-01-17 重庆医科大学 普雷沃氏菌在防治注意缺陷多动障碍中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163799A (en) * 1975-06-13 1979-08-07 Union Chimique Continentale U.C.C. Psychostimulant compounds
US4202897A (en) * 1977-07-25 1980-05-13 Sandoz, Inc. Prolactin secretion inhibitors
US4148906A (en) * 1977-12-30 1979-04-10 Platon J. Collipp Growth hormone inhibitors
IT1194359B (it) * 1983-08-01 1988-09-22 Stabil Bioterapico Farmachim Applicazione terapeutica del mazindolo nella malattia di parkinson
US5217987A (en) * 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
ATE277594T1 (de) * 1998-06-03 2004-10-15 Alza Corp Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
EP1165054A4 (en) * 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
US20020161002A1 (en) * 2001-01-02 2002-10-31 Mel Epstein Use of catecholamine reuptake inhibitors to enhance memory
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
WO2004091546A2 (en) * 2003-03-31 2004-10-28 Euro-Celtique S.A. Central nervous system stimulant and opioid antagonist combinations
EP1635804B1 (fr) * 2003-05-30 2016-09-21 NLS-1 Pharma AG Utilisation du fer pour le traitement du trouble du deficit de attention/hyper-activite chez les enfants
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite

Also Published As

Publication number Publication date
CA2648943A1 (fr) 2007-10-18
TNSN08397A1 (fr) 2010-04-14
EP2004183A1 (fr) 2008-12-24
US20110223260A2 (en) 2011-09-15
AU2007235860A1 (en) 2007-10-18
US20110183009A1 (en) 2011-07-28
JP2013189467A (ja) 2013-09-26
CN104013620A (zh) 2014-09-03
US20170252325A1 (en) 2017-09-07
EP2004183B1 (fr) 2013-06-26
CN101420953A (zh) 2009-04-29
ES2427570T3 (es) 2013-10-31
WO2007116076A1 (fr) 2007-10-18
AU2007235860B2 (en) 2012-05-24
US20160030394A1 (en) 2016-02-04
US20190328714A1 (en) 2019-10-31
NZ572002A (en) 2012-03-30
FR2899476B1 (fr) 2008-07-04
MA30330B1 (fr) 2009-04-01
ES2816629T3 (es) 2021-04-05
US20170216258A1 (en) 2017-08-03
PL2564872T3 (pl) 2021-03-08
US20120308668A1 (en) 2012-12-06
JP2009533388A (ja) 2009-09-17
CA2648943C (fr) 2017-10-24
US8293779B2 (en) 2012-10-23
IL194623A (en) 2015-03-31
US20210093614A1 (en) 2021-04-01
EP2564872A1 (fr) 2013-03-06
IL194623A0 (en) 2009-08-03
US20090136593A1 (en) 2009-05-28
FR2899476A1 (fr) 2007-10-12
PL2004183T3 (pl) 2013-11-29
EP2564872B1 (fr) 2020-06-10
US20240108605A1 (en) 2024-04-04
PT2004183E (pt) 2013-09-24

Similar Documents

Publication Publication Date Title
DK2004183T3 (da) Mazindol-kombination i behandlingen af opmærksomhedsunderskud/hyperaktivitet
DK2175851T3 (da) Biofilmbehandling
BRPI0717339A2 (pt) Reversor de empuxo e nacela de turboélice
BRPI0807908A2 (pt) Melhoramentos em composições medicinais.
DK2350116T3 (da) Behandling af biofilm
ATE526567T1 (de) Zusammensteller und zusammenstellungsverfahren
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2200600T3 (da) Neramexan til anvendelse ved behandlingen af subakut tinnitus
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK1888471T3 (da) Anaerobt rensningsanlæg
DK2173831T3 (da) Brøndbehandling
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
DK1933840T3 (da) Anvendelse af delmopinol i behandlingen af acne
BRPI0810762A2 (pt) Composição para tratamento da água
DK2004214T3 (da) Lokalbehandling med faktor VII
BRPI0817439A2 (pt) gaseificador
DK2297047T3 (da) Indretning til rensning af spildevand
DK2107906T3 (da) Hidtil ukendt terapeutisk anvendelse til behandling af leukæmier
DK2001499T3 (da) Anvendelse af TGS-6 til behandling af osteoporose
DE102007047112A8 (de) Strahlregler
DK2168922T3 (da) Anlæg til behandling af spildevand
DE112008004261A5 (de) Schichtabscheidevorrichtung und Schichtabscheideverfahren
FI7219U1 (fi) Hoitopöytä
FI20070640A0 (fi) Jätteenkäsittely-yksikkö
TH99984B (th) อ่างล้างหน้า